Proton MR spectroscopy of the brain at 3 T: an update

被引:0
作者
Alfonso Di Costanzo
Francesca Trojsi
Michela Tosetti
Timo Schirmer
Silke M. Lechner
Teresa Popolizio
Tommaso Scarabino
机构
[1] Second University of Naples,Department of Neurological Sciences
[2] Scientific Institute “Stella Maris”,Magnetic Resonance Laboratory
[3] Applied Science Laboratory,GE Healthcare
[4] GE Global Research,Department of Neuroradiology
[5] Scientific Institute “Casa Sollievo della Sofferenza”,Department of Health Sciences
[6] University of Molise,undefined
来源
European Radiology | 2007年 / 17卷
关键词
Magnetic resonance spectroscopy; Brain; Diagnostic imaging;
D O I
暂无
中图分类号
学科分类号
摘要
Proton magnetic resonance spectroscopy (1H-MRS) provides specific metabolic information not otherwise observable by any other imaging method. 1H-MRS of the brain at 3 T is a new tool in the modern neuroradiological armamentarium whose main advantages, with respect to the well-established and technologically advanced 1.5-T 1H-MRS, include a higher signal-to-noise ratio, with a consequent increase in spatial and temporal resolutions, and better spectral resolution. These advantages allow the acquisition of higher quality and more easily quantifiable spectra in smaller voxels and/or in shorter times, and increase the sensitivity in metabolite detection. However, these advantages may be hampered by intrinsic field-dependent technical issues, such as decreased T2 signal, chemical shift dispersion errors, J-modulation anomalies, increased magnetic susceptibility, eddy current artifacts, challenges in designing and obtaining appropriate radiofrequency coils, magnetic field instability and safety hazards. All these limitations have been tackled by manufacturers and researchers and have received one or more solutions. Furthermore, advanced 1H-MRS techniques, such as specific spectral editing, fast 1H-MRS imaging and diffusion tensor 1H-MRS imaging, have been successfully implemented at 3 T. However, easier and more robust implementations of these techniques are still needed before they can become more widely used and undertake most of the clinical and research 1H-MRS applications.
引用
收藏
页码:1651 / 1662
页数:11
相关论文
共 330 条
[1]  
Bonavita S(1999)Proton MRS in neurological disorders Eur J Radiol 30 125-131
[2]  
Di Salle F(2002)In vivo neurochemistry with emission tomography and magnetic resonance spectroscopy: clinical applications Eur Radiol 12 2582-2599
[3]  
Tedeschi G(2005)Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making NeuroRx 2 197-214
[4]  
Del Sole A(2004)H MR chemical shift imaging detection of phenylalanine in patients suffering from phenylketonuria (PKU) Eur Radiol 14 1895-1900
[5]  
Gambini A(2005)H chemical shift imaging of the brain in guanidino methyltransferase deficiency, a creatine deficiency syndrome; guanidinoacetate accumulation in the gray matter Eur Radiol 15 1923-1926
[6]  
Falini A(2002)Proton magnetic resonance spectroscopy of the brain of a neonate with nonketotic hyperglycinemia: in vivo-in vitro (ex vivo) correlation Eur Radiol 12 858-861
[7]  
Lecchi M(2000)Reversible brain creatine deficiency in two sisters with normal blood creatine level Ann Neurol 47 511-513
[8]  
Lucignani G(2006)Short TE quantitative proton magnetic resonance spectroscopy in variant Creutzfeldt-Jakob disease Eur Radiol 12 1-7
[9]  
Lin A(2005)MR relaxometry and 1H MR spectroscopy for the determination of iron and metabolite concentrations in PKAN patients Eur Radiol 15 1060-1068
[10]  
Ross BD(2003)Diffusion MRI and spectroscopy in Rasmussen’s encephalitis Eur Radiol 13 2186-2191